1. Home
  2. NTRB vs MYO Comparison

NTRB vs MYO Comparison

Compare NTRB & MYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nutriband Inc.

NTRB

Nutriband Inc.

N/A

Current Price

$5.86

Market Cap

72.6M

Sector

Health Care

ML Signal

N/A

Logo Myomo Inc.

MYO

Myomo Inc.

N/A

Current Price

$1.34

Market Cap

63.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NTRB
MYO
Founded
2016
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.6M
63.8M
IPO Year
2019
2017

Fundamental Metrics

Financial Performance
Metric
NTRB
MYO
Price
$5.86
$1.34
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
★ $4.64
AVG Volume (30 Days)
27.3K
★ 217.8K
Earning Date
12-10-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
$2,036,651.00
★ $1,000,000,000.00
Revenue This Year
$4,584.65
$11.43
Revenue Next Year
$89.09
$12.29
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 40814.79
52 Week Low
$2.80
$0.61
52 Week High
$9.19
$1.89

Technical Indicators

Market Signals
Indicator
NTRB
MYO
Relative Strength Index (RSI) 43.98 51.43
Support Level $5.68 $1.17
Resistance Level $6.66 $1.75
Average True Range (ATR) 0.39 0.11
MACD -0.05 0.02
Stochastic Oscillator 31.80 55.29

Price Performance

Historical Comparison
NTRB
MYO

About NTRB Nutriband Inc.

Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.

About MYO Myomo Inc.

Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.

Share on Social Networks: